Leadership Views - Cancer Currents Blog
- NCI ALMANAC: A New Tool for Research on Cancer Drug Combinations
NCI has released a new, easy-to-use resource called the NCI ALMANAC to help researchers identify potentially promising combinations of cancer drugs.
- Making Greater Progress Against Cancer—Not Just a Hope but a Reality
Acting NCI Director Dr. Doug Lowy discusses what he calls encouraging news in the most recent Annual Report to the Nation and how NCI is helping to achieve further progress against cancer.
- Advancing the Potential and Promise of Total-Body PET Imaging
A total-body PET scanner under development is an ideal example of how NCI and NIH are supporting the development of new research and cancer care-related technologies.
- Colorectal Cancer Incidence Rising in Young Adults: An Interview with Drs. Philip Rosenberg and William Anderson
Drs. Philip Rosenberg and William Anderson of NCI discuss a recent study on which they were coauthors that reported an increase in colorectal cancer incidence among adults under age 50 in the United States.
- Putting the Cancer Patient Front and Center: An Interview with NCI’s Dr. Paul Jacobsen
NCI’s Dr. Paul Jacobsen discusses NCI’s Healthcare Delivery Research Program and its role in advancing innovative research to improve the delivery of cancer care.
- Conditional Reprogramming: An Interview with Dr. Richard Schlegel on Growing Cancer Cells
Dr. Richard Schlegel describes an innovative cell culture technique he helped to develop. Called conditional reprogramming, the technique can be used to rapidly establish cell cultures of normal and tumor cells from patient samples.
- Cancer Moonshot Moves Forward, Bringing Funding Opportunities for Researchers
NCI has issued a series of funding opportunity announcements aligned with goals of the recommendations in the Beau Biden Cancer Moonshot℠ Blue Ribbon Panel report released last fall.
- NCTN/NCORP Data Archive: Expanding Access to Clinical Trial Data
NCI is launching the NCTN/NCORP Data Archive, a centralized repository of patient-level data from phase III clinical trials conducted by NCI’s NCTN and NCORP trials programs and the National Cancer Institute of Canada-Clinical Trials Group.
- The Global Economic Burden of Tobacco: An Interview with Dr. Mark Parascandola
NCI’s Dr. Mark Parascandola answers questions about The Economics of Tobacco and Tobacco Control, the latest in a series of monographs on tobacco use and tobacco control, which was co-written with the World Health Organization.
- NCI’s Office of Cancer Survivorship: Celebrating 20 Years, Planning for Continued Progress
Dr. Julia Rowland, director of NCI’s Office of Cancer Survivorship, on the office’s 20th anniversary and efforts to ensure continued progress in survivorship research and improve survivors’ lives.
- Connected Health: An Important Tool for Making Progress against Cancer
A new report from the President’s Cancer Panel outlines how connective technologies can promote cancer prevention, enhance patients’ treatment experience, and accelerate progress in cancer research.
- Educating Patients about Genetic Test Results: An Interview with Carol Weil about the COMET Study
The recently launched COMET study will examine whether educating patients with cancer about genetic testing will increase their knowledge and reduce their stress levels after receiving genomic testing results.
- Forging Collaborations to Spur Global Progress against Cancer
NCI and NIH announce efforts to establish international collaborations that can accelerate progress in reducing the global cancer burden.
- Meeting Patients Where They Are: Liberating Clinical Trials Data Under the Cancer Moonshot
NCI’s new application programming interface (API) that allows anyone to build online tools that help people find NCI-supported clinical trials.
- Blue Ribbon Panel Report: The Power of the Cancer Community Coming Together
NCI Acting Director Dr. Douglas R. Lowy, M.D., thanks the cancer community for contributing to the Cancer Moonshot Blue Ribbon Panel report, which was presented to the National Cancer Advisory Board on September 7.
- Setting the Stage for the Next Decade of Tobacco Control Research
A new report from an NCI working group lays out recommended priorities to help shape the institute’s future tobacco control research portfolio.
- The Moonshot Blue Ribbon Panel: Moving Toward a Final Report
An update on the activities of the National Cancer Moonshot Initiative’s Blue Ribbon Panel and its work to develop a final report for research ideas to be pursued under this initiative.
- Charting a Course toward Precision Cancer Prevention
Cancer researchers are increasingly exploring how cancer risk is influenced by genetic predisposition to cancer and the effects of environmental exposures, and what this means for cancer prevention.
- Improving Cancer Control in Rural Communities: An Interview with Dr. Robert Croyle
NCI’s Dr. Robert Croyle discusses some of the issues related to cancer control faced by rural communities and how NCI is approaching this important problem.
- Improving Public Health through Increased Tobacco Regulation
NCI’s Dr. Robert Croyle discusses the Food and Drug Administration’s release of a rule that extends its regulatory authority over tobacco products to include cigars, e-cigarettes, hookah (waterpipe) tobacco.
- Calling on Data Enthusiasts to Help Advance Cancer Research
Health data enthusiasts of all stripes were in Washington, D.C., today for Health Datapalooza. NCI's Dr. Warren Kibbe explains that this annual event explores a topic that is central to NCI’s efforts against cancer: creating knowledge from data.
- The Cancer Community's Next Steps for the Moonshot Initiative
The National Cancer Moonshot Initiative’s Blue Ribbon Panel is moving quickly to develop recommendations on how to accelerate progress against cancer.
- A Shared Commitment for Accelerating Progress with the Cancer Moonshot
At the AACR annual meeting, Vice President Biden spoke about the National Cancer Moonshot Initiative and the critical role the entire research community will play in accelerating progress against cancer.
- Toward Precision Therapy for Children with Cancer: An Interview with Dr. Javed Khan
NCI’s Dr. Javed Khan discusses a new NCI clinical program and the promise and challenges of genome-guided therapy for children with cancer.
- Fueling Basic Discovery: NCI’s Cooperative Human Tissue Network
Quality biospecimens are a foundational resource for cancer research. One of NCI’s longest running biospecimen programs is the Cooperative Human Tissue Network, a resource mainly for basic discovery and early translational research.
- NCI-DOE Collaboration Paving Way for Large-Scale Computational Cancer Science
NCI and the Department of Energy have entered into a collaboration to develop a plan to use large-scale computing to influence cancer science and, ultimately, clinical treatment.
- President Obama’s Budget Request Affirms Commitment to Progress against Cancer
President Obama’s FY 2017 Budget Request includes $680 million to support Vice President Biden’s cancer research initiative.
- Tackling the Global Cancer Burden: A Conversation with NCI’s Dr. Ted Trimble
In honor of World Cancer Day, the director of NCI’s Center for Global Health discusses key opportunities in global cancer research.
- Opportunities in Cancer Nanotechnology: A Conversation with NCI’s Dr. Piotr Grodzinski
The director of NCI's Office of Cancer Nanotechnology Research discusses the Cancer Nanotechnology Plan 2015, as well as new developments and clinical opportunities in the field.
- Supporting Vice President Biden's Cancer Initiative
During his 2016 State of the Union address to Congress, President Obama tasked Vice President Biden with leading a new initiative to accelerate cancer research. This message from NCI Acting Director Doug Lowy states that the Institute stands ready to work with partners across the cancer research community on the initiative.
- Driving New Approaches to Cancer Prevention and Early Detection
Researchers are pioneering new approaches to preventing and screening for cancer, and the management of very early-stage disease.
- Lung Cancer Precision Medicine Trials: Adapting to Progress
Patients with lung cancer are benefiting from the boom in targeted and immune-based therapies. With a series of precision medicine trials, NCI is keeping pace with the rapidly changing treatment landscape for lung cancer.
- How Genomics Is Shaping Precision Medicine in Oncology
In laboratories at NCI and around the world, researchers are using advanced genomic technologies to study the differences between cancer cells and normal cells, leading to new and more effective treatments for patients with cancer.
- Bringing Cancer Research to the Public: NCI’s Networks and Programs
A number of NCI programs and networks are the foundation of the National Cancer Program and play a critical role in promoting progress.
- Progress against Cancer: The Role of Basic Science
Acting NCI Director Doug Lowy, M.D., discusses the critical contribution of basic science in fostering progress against cancer.
- Cancer Trends: Influencing Care and Research Priorities
Many of the trends being seen in cancer are changing how we view cancer and how we address it, from prompting research to identify the underlying causes of cancers increasing in incidence to informing research on treatment and prevention.
- CPTAC, the Complementary Sibling of TCGA: An Interview with Dr. Henry Rodriguez about NCI’s Proteomics Program
Dr. Henry Rodriguez explains the goals and future directions of CPTAC, a collaborative consortium of institutions and investigators who study cancer proteomics.
- Setting the Course: Genomics Workshop on Childhood Cancers Identifies Research Opportunities
NCI recently convened a workshop to discuss the status of genomic characterization for childhood cancers and to identify opportunities for future research.
- Future Directions for NCI’s Surveillance Research Program
Since the early 1970s, NCI’s SEER program has been an invaluable resource for statistics on cancer in the United States. For the past several years, SEER researchers have been working toward a much broader and comprehensive goal for providing cancer statistics on a nationwide basis.
- Microscopy Advances Open Up New Avenues of Cancer Discovery
Today’s high-powered microscopes are allowing researchers to study the fine details of individual cells and to peer into cells, opening up new avenues of discovery about the inner workings of cells, including the events that can cause healthy cells to transform into cancer cells.
- Advancing Cancer Care Delivery Research in the Next Decade
A more substantial and coordinated effort is needed to advance the science of cancer care delivery to help address the complex problems facing our health care systems. In response, NCI has created a new Healthcare Delivery Research Program (HDRP) to strengthen its support and coordination of research in ways that both improve survival and enhance patient care experiences.
- Facilitating Research, Fueling Collaboration: Dr. Frank McCormick on the RAS Initiative
Frank McCormick, Ph.D., talks about the history, the challenges, and the future of research on RAS gene mutations, which drive more than 30 percent of all human cancers.
- The Cancer Genome Atlas: Generating a "Parts List" for Cancer
Jean-Claude Zenklusen, Ph.D., discusses the accomplishments and future of The Cancer Genome Atlas, inspired by topics covered in the documentary film, Cancer: The Emperor of All Maladies.